Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bcr-2021-243469 http://scihub22266oqcxt.onion/10.1136/bcr-2021-243469 34344651!8336168!34344651     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       BMJ+Case+Rep 2021 ; 14 (8): ä Nephropedia Template TP {{tp|p=34344651|t=2021. Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab |pdf=|usr=}}{{34344651}} gab.com Text Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab JO: BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=34344651 #FOAvip As we are over a year into the COVID-19 pandemic, we have made many forward strides in therapeutics. These treatments, such as monoclonal antibodies, have help mitigate the detrimental and often fatal consequences of COVID-19. The current indication for the use of monoclonal antibodies is mild to moderate COVID-19 infection within 10 days of symptom onset in those who are at high risk of progression to severe disease. However, their role in patients with prolonged symptoms is not clear. We present a unique case of monoclonal antibodies use after 54 days of symptom onset in an immunosuppressed patient with persistent COVID-19 infection despite standard treatment. This case illustrates the potential use of monoclonal antibodies outside of the current recommended therapeutic window in immunosuppressed patients, who may have difficulty with viral clearance. Twit Text FOAVip Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab ????BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=34344651 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34344651 #FOAvip English Wikipedia <ref>{{Cite pmid|34344651}}</ref> Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab #MMPMID34344651 Rabascall CX; Lou BX; Navetta-Modrov B; Hahn SS BMJ Case Rep 2021[Aug]; 14 (8): ä PMID34344651show ga As we are over a year into the COVID-19 pandemic, we have made many forward strides in therapeutics. These treatments, such as monoclonal antibodies, have help mitigate the detrimental and often fatal consequences of COVID-19. The current indication for the use of monoclonal antibodies is mild to moderate COVID-19 infection within 10 days of symptom onset in those who are at high risk of progression to severe disease. However, their role in patients with prolonged symptoms is not clear. We present a unique case of monoclonal antibodies use after 54 days of symptom onset in an immunosuppressed patient with persistent COVID-19 infection despite standard treatment. This case illustrates the potential use of monoclonal antibodies outside of the current recommended therapeutic window in immunosuppressed patients, who may have difficulty with viral clearance. |*COVID-19[MESH] |Antibodies, Monoclonal/therapeutic use[MESH] |Humans[MESH] |Pandemics[MESH] |Rituximab/therapeutic use[MESH]Effective use of monoclonal antibodies for treatment of persistent COV(epmc).pdf DeepDyve Pubget Overpricing